Do try not to be misleading in your analysis. You may have heard of sample size amongst your trolling. n=1 doesn't really past muster Pledge. Thought you'd have worked that out by now. Do be thorough and tell us all of the ones discussed (this not even recent):
"Most recently, IQVIA released a report finding that 25 of 59 (42%) novel drugs approved in 2018 were approved on the basis of only one trial. And one out of eight approvals relied only on Phase 1 or 2 trials, with no Phase 3 trials. But as in previous years, a large portion of the drugs relying on only one trial were new orphan and cancer drugs."
https://www.raps.org/News-and-Articles/News-Articles/2019/5/Almost-Half-of-All-New-Drug-Approvals-in-2018-ReliYour actual one example OF MANY actually even refutes your very statement above of none reaching commercialisation:
"the company will remove the drug from market".
Ergo it was in the market. You can't even read your own reports properly that prove exactly your earlier statement as incorrect.
So yeah, "next".
(20min delay)